Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder

Research output: Contribution to journalArticle

265 Scopus citations

Abstract

Cyclooxygenase (COX)-inhibiting drugs have antitumor activity in canine and rodent models of urinary bladder cancer. Two isoenzymes of COX have been identified, COX-1 and COX-2. The purpose of this study was to characterize COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by immunohistochemistry and Western blot analysis. COX-2 was not expressed in normal urinary bladder samples but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and in 6 of 8 (75%) cases of carcinoma in situ. These results indicate that COX-2 may play a role in bladder cancer in humans and support further study of COX- 2 inhibitors as potential antitumor agents in human bladder cancer.

    Fingerprint

Cite this

Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N. M., Masferrer, J. L., Woerner, B. M., Snyder, P. W., & Koki, A. T. (1999). Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Research, 59(22), 5647-5650.